In conclusion, AML patients with IDH2 R140 mutations tend to achieve more rapid and complete blast cytoreduction following intensive induction compared with IDH2 R172, while IDH1‐mutated patients showed comparable outcomes to the IDH2 group overall. The gene discussed is IDH1; the disease is acute myeloid leukemia.